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According to the American Medical Association, attention
deficit hyperactivity disorder (ADHD) is ‘‘one of the best-
researched disorders in medicine, and the overall data on its
validity are far more compelling than for most mental
disorders and even for many medical conditions’’ (1).
Despite the robust body of research that makes ADHD
one of the ‘‘best-researched disorders in medicine’’, there is
still a lack of knowledge about this disorder in Brazil. To
address this gap, we present an overview of the current
scientific understanding of ADHD.
ADHD is a chronic disorder with onset in childhood that
affects approximately 5% of children and adolescents
worldwide, irrespective of the country in which they live
(2). The disorder persists into early adulthood in approxi-
mately 65-75% of cases (3). ADHD has a variable clinical
presentation that includes inattentiveness, hyperactivity or
impulsivity (4). The symptoms of ADHD cause significant
functional impairment, such as social and family life
problems, low educational attainment and an increased
school dropout risk; this functional impairment frequently
leads to low self-esteem and has a negative influence on
emotional development (4). ADHD is also associated with
negative physical outcomes, such as injuries, including
traffic accidents, premature pregnancy, and sexually trans-
mitted diseases, among others. Individuals with ADHD are
also at significant risk of concurrent or future psychiatric
comorbidities, such as conduct disorder, anxiety and mood
disorders, antisocial behavior and substance abuse (5).
The diagnosis is established according to reliable clinical
criteria, which require a persistent pattern of inattention
and/or hyperactivity-impulsivity that must be maladaptive
and inconsistent with the developmental age of the child (6).
The symptoms should cause clinically significant impair-
ment in social, academic, or occupational functioning. The
symptoms must occur often, in more than one setting, and
must have persisted for at least six months. Additionally,
the diagnosis is only made if at least some of the behavioral
symptoms were present before the age of seven years (6).
Presently, there are no biological, electrophysiological or
neuroimaging markers with clinical utility for the diagnosis
of ADHD. Therefore, clinical skills and knowledge are
essential for establishing an accurate diagnosis because
ADHD symptoms must be differentiated from normal
development and other causes must be excluded. In
addition, comorbid disorders must be identified.
Etiological studies evaluating families, adopted children
and twins with ADHD have identified a strong genetic
contribution, with a pooled heritability rate of 76% (7). Meta-
analyses have identified genes involved in the dopaminergic
and serotoninergic systems, among other systems, as suscept-
ibility genes. Environmental factors, such as intra-uterine
exposure to tobacco, prematurity and low birth weight also
seem to increase the susceptibility to ADHD (5). Similar to data
for other complex diseases, such as cardiovascular disease and
diabetes, the current data for ADHD suggest that multiple risk
alleles with small effects and environmental factors are
involved in the etiology of ADHD. Emerging evidence also
suggests an important role of copy number variations (8).
Neuropsychological and neuroimaging studies have
demonstrated a clear biological substrate for ADHD,
implicating neural systems and areas involved in attention,
inhibitory control and other executive functions (9). Many
different studies have demonstrated that neural networks in
the dorsolateral prefrontal cortex, the dorsal anterior
cingulate, the parietal, striatum, and the cerebellum are
primarily involved in ADHD (9,10). In addition, a landmark
study conducted by the US National Institute of Mental
Health demonstrated a marked delay in brain maturation in
children with ADHD, with the peak cortical thickness
occurring approximately three years later in children with
ADHD than in healthy controls. The delay was most
prominent in the prefrontal regions linked to the mechan-
isms of attention control and executive functions (11).
More than 200 randomized controlled trials have evaluated
pharmacological, psychosocial and alternative treatments for
ADHD (12).Medication results inmarked improvements in the
cardinal symptoms and is the first-choice treatment for school-
age children, adolescents and adults (12). However, behavioral
intervention is the first-choice treatment for preschoolers.
Stimulants are the first-line medications and have been used
to treat ADHD for several decades, with consistent data
demonstrating the efficacy and safety of these drugs (13).
Stimulants (e.g., methylphenidates and amphetamines) have a
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pooled effect size of 0.7-1 for children and 0.7-0.9 for adults for
the reduction of ADHD symptoms (14,15). Non-stimulants
(e.g., atomoxetine and clonidine) have a pooled effect size of 0.6
for children and 0.4 for adults for the same symptoms (12,14).
Despite the robust ability of medications to reduce ADHD
symptoms, there is increasing recognition of the relevance
of a comprehensive approach with multimodal interven-
tions that also target the associated conditions, such as
school difficulties, family dysfunction, low self-esteem and
comorbid disorders (5). It is important to identify the target
outcomes to formulate the best treatment plan. For most
patients, other interventions of varying type and intensity
are needed. The individual’s needs dictate which profes-
sionals are involved in the treatment and which techniques
should be used (13).
In conclusion, ADHD is an extensively studied disorder,
with consistent high-quality data demonstrating its validity.
Children and adolescents with ADHD exhibit significant
impairment and are at increased risk of deficits in social,
emotional and educational development. Although there
are concerns about misdiagnosis, which may be related to
the small number of well-trained professionals in the field,
studies conducted in Brazil indicate that approximately 95%
of children with ADHD do not receive treatment (16). The
lack of adequate training, stigma, and misconceptions are
important barriers to the recognition and treatment of
ADHD and must be actively combated.
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